Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 10/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15001764 | 0.89 | MRGPRX4 (0.55) | HPGDPARP1MRGPRX4 | |
| SCHEMBL16488686 | 0.88 | CYP4F2 (0.47) | PARP1MRGPRX4 | |
| SCHEMBL15002582 | 0.86 | KDM4E (0.56) | ALDH1A1PARP1MRGPRX4 | |
| SCHEMBL15001698 | 0.84 | PARP1 (0.60) | PARP1 | |
| SCHEMBL19184571 | 0.82 | PARP1 (0.61) | ALDH1A1HPGDPARP1 | |
| SCHEMBL15002417 | 0.81 | PARP1 (0.58) | PARP1 | |
| SCHEMBL17356392 | 0.79 | PARP1 (0.52) | MAOBALDH1A1HPGDPARP1ALPL | |
| SCHEMBL16207560 | 0.78 | PARP1 (0.72) | ALDH1A1HPGDPARP1 | |
| SCHEMBL19998367 | 0.78 | MAOA (0.47) | MAOBPARP1MAOA | |
| SCHEMBL16215129 | 0.78 | PARP1 (0.67) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718787-B2 | Poly (ADP-ribose) polymerase inhibitor | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-08-01 | — | — | US | disclosed |
| US-20150368205-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368205-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | PARP1, PARP2, PARP11 | MAOB 1138/4885ALDH1A1 607/4885HPGD 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.